Replies to post #2310 on Cocrystal Pharma Inc (COCP)

[mick]

#2, https://finance.yahoo.com/news/cocrystal-pharma-provides-covid-19-120510979.html

BOTHELL, WA, May 11, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),
(“Cocrystal” or the “Company”), a clinical stage biotechnology
company discovering and developing novel antiviral therapeutics,

today provided an update on the impact of the COVID-19 global pandemic on its preclinical and clinical development programs.

“We have reprioritized development activities to accelerate the advancement of our preclinical COVID-19 program,
which we recently established as a result of our license agreements
with Kansas State University Research Foundation (KSRF),”
commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal.

“Like many of our peers, we have been working to minimize the impact of the COVID-19 pandemic on our operations.

While we have been able to mitigate some of the risks,
the worldwide impact on supply chains has resulted in a delay to our fully owned influenza A virus program.

The full impact of COVID-19 on our development programs remains uncertain, but our team is determined to advance preclinical and clinical
development programs across our pipeline as quickly and efficiently as possible.”

Programs Update

Influenza A/B Inhibitors: Merck Collaboration

Cocrystal’s exclusive license and collaboration agreement with
Merck to discover and develop certain proprietary influenza A/B antiviral agents remains ongoing.

Cocrystal has been working with the scientific leadership at Merck
over the past year in advancing the joint influenza A/B program.

Merck, a global healthcare company with a history of over 125-years of drug discovery and innovation,
has funded the collaborative influenza A/B program and could provide
up to $156 million in milestones payments as the collaboration
proceeds through clinical and commercial development.

The research and collaboration agreement with Merck also provides for royalties following commercialization.

CC-42344: Influenza A Program

The Company’s lead molecule in development, CC-42344, is currently
being evaluated in preclinical IND-enabling studies for the treatment
of influenza.

CC-42344 has shown excellent antiviral activity against influenza
A strains, including avian pandemic strains and Tamiflu® resistant strains, and shows a favorable pharmacokinetic and safety profile.